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Abstract
Objective—To model outcomes in laparoscopic hysterectomy with morcellation compared to 
abdominal hysterectomy for the presumed fibroid uterus, examining short-and long-term 
complications, as well as mortality.
Study Design—A decision tree was constructed to compare outcomes for a hypothetical cohort 
of 100,000 premenopausal women undergoing hysterectomy for presumed fibroids over a 5-year 
time horizon. Parameter and quality of life utility estimates were determined from published 
literature for postoperative complications, leiomyosarcoma incidence, death related to 
leiomyomsarcoma, and procedure-related death.
Results—The decision analysis predicted fewer overall deaths with laparoscopic hysterectomy 
compared to abdominal hysterectomy (98 vs. 103 per 100,000). While there were more deaths 
from leiomyosarcoma following laparoscopic hysterectomy (86 vs. 71 per 100,000), there were 
more hysterectomy-related deaths with abdominal hysterectomy (32 vs. 12 per 100,000). The 
laparoscopic group had lower rates of transfusion (2,400 vs. 4,700 per 100,000), wound infection 
(1,500 vs 6,300 per 100,000), venous thromboembolism (690 vs. 840 per 100,000) and incisional 
hernia (710 vs. 8,800 per 100,000), but a higher rate of vaginal cuff dehiscence (640 vs. 290 per 
100,000). Laparoscopic hysterectomy resulted in more quality-adjusted life years (499,171 vs. 
490,711 over five years).
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Conclusion—The risk of leiomyosarcoma morcellation is balanced by procedure-related 
complications associated with laparotomy, including death. This analysis provides patients and 
surgeons with estimates of risk and benefit, upon which patient-centered decisions can be made.
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Introduction
Hysterectomy is the most common procedure performed in non-pregnant women in the 
United States, with leiomyomata (fibroids) the indication for a significant proportion of 
these.1 Surgeons are increasingly employing laparoscopy for hysterectomy.2 For all 
laparoscopic supracervical hysterectomies and total laparoscopic hysterectomies where the 
specimen is too large to be removed intact vaginally, the uterus must be morcellated—i.e. 
cut into pieces which will fit through small incisions. If morcellation is not contained in a 
retrieval bag, tissue may be unintentionally left behind, which can lead to spread of benign 
or malignant tissue.3,4
Morcellation has come under scrutiny regarding the risk of disseminating occult 
leiomyosarcoma, highlighted by a recent Food and Drug Administration safety notification.5 
Unlike other gynecologic malignancies, leiomyosarcoma is difficult to distinguish from 
benign disease preoperatively and bears a poor prognosis.6 Retrospective studies suggest a 
worse prognosis with morcellation of leiomyosarcoma compared to intact removal of the 
uterus.7,8
Laparoscopic hysterectomy affords shorter hospital stay and convalescence compared to 
abdominal hysterectomy. In addition, laparoscopic hysterectomy is associated with less pain, 
lower blood loss, and lower rates of wound infection, incisional hernia, and venous 
thromboembolism.9 On the other hand, abdominal hysterectomy avoids the risk of 
morcellating leiomyosarcoma. To provide physicians with better estimates of health 
outcomes when considering these surgical approaches, we conducted a decision analysis 
comparing laparoscopic hysterectomy to abdominal hysterectomy for the management of the 
enlarged uterus with presumed benign leiomyomata in premenopausal women, examining 
mortality, surgical complications, and quality of life.
Materials and Methods
We constructed a decision tree to compare outcomes of laparoscopic hysterectomy with 
morcellation to abdominal hysterectomy for women with an enlarged uterus due to 
presumed benign leiomyomata (Figure 1). We assessed a hypothetical cohort of 100,000 
premenopausal women, as approximately 200,000 hysterectomies are performed for 
leiomyomata annually in the United States.1 It made clinical sense that roughly half of those 
could involve uteri large enough to require morcellation if considered for laparoscopic 
hysterectomy. The decision tree model was constructed using Excel ™ 2010 (Microsoft 
Corp, Redmond, Washington) and TreePlan ™ (TreePlan Software, San Francisco, 
California).
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Women undergoing both laparoscopic and abdominal hysterectomy were at risk for potential 
surgical complications, each represented as unique and independent health states in the 
model. Morbidity and mortality outcomes were evaluated over a 5-year time horizon. This 
study was considered exempt from review by the Institutional Review Board at the 
University of North Carolina at Chapel Hill as it involved analysis of existing published 
data. S.W., S.R., and M.S. were responsible for analyzing data.
Base-case estimates and ranges for each parameter, as well as transition probabilities 
governing movement between branches in the decision tree, were determined by published 
literature review (Table 1). In selecting estimates, preference was given to higher quality 
studies and more recent publications, reflecting advances in surgical practice. Surgical 
complications in the model included transfusion, abdominal wound infection, vaginal cuff 
dehiscence, venous thromboembolism, incisional hernia, leiomyosarcoma, death from 
leiomyosarcoma, and death from hysterectomy. Febrile episodes and vaginal cuff infections 
were considered but felt better represented by identifiable and more objective diagnoses, 
wound infection and cuff dehiscence. Major visceral and vascular adverse events were not 
included as they are rare and not significantly different between laparoscopic and abdominal 
hysterectomy.10
Mortality rates due to hysterectomy were reflected in the literature as a short-term outcome 
and were not categorized by a specific cause (e.g. fatal embolic event). Excluding older 
studies conducted when safety and prophylactic measures (e.g. infection, venous 
thromboembolism) were different from modern practice,11,12 estimates of 0.00012 
(laparoscopic hysterectomy) and 0.00032 (abdominal hysterectomy) were derived from three 
larger and more recent series.13-15
In terms of occult malignancy, we focused on leiomyosarcoma in particular as it mimics 
benign myomatous disease. Other more rare uterine mesenchymal tumors have diverse 
biologic behavior and the impact of morcellation on these tumors is unknown. Cerivical 
cancer is almost always a known preoperative diagnosis, and the risk of tissue dissemination 
appears to be less serious with endometrial cancer.16 Ten sources were considered regarding 
the incidence of leiomyosarcoma among women undergoing hysterectomy for presumed 
fibroids (Table 2).4, 17-25 Quality and the degree to which the study population mirrored that 
for our decision analysis was evaluated based on year of publication, menopausal status, 
number of subjects, geographical location, and pathologic criteria used to determine 
leiomosarcoma diagnosis. An estimate of 0.0012 (6/5084) was derived from what were 
considered the four highest quality sources, reporting mean estimates of 0.0008,19 0.0007,22 
0.0009,4 and 0.0023.23 The range for sensitivity analysis included those with sample size 
greater than 1,000: 0.000722 to 0.0049.17
Leiomyosarcoma mortality estimates were derived from Surveillance, Epidemiology, and 
End Results reports.26 First, we assumed women with metastatic disease would generally be 
identified pre-operatively and not candidates for our hypothetical cohort. In rare cases when 
it was not, surgical approach, with or without morcellation, would not change their stage 
(IV) and nor impact overall survival, which would be driven by the distant metastases. 
Therefore, occult leiomyosarcoma detected at the time of hysterectomy would be 
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represented in the model by an International Federation of Obstetrics and Gynecology stage 
I or stage II (confined to the pelvis) diagnosis, with a 5-year mortality of 0.59. Second, we 
assumed morcellation could lend the same prognosis as spontaneous cancer spread, and thus 
the laparoscopic group was assigned a stage III (extra-pelvic disease) prognosis, with a 5-
year mortality of 0.72 (i.e. all laparoscopic patients given a worse prognosis than abdominal 
patients).
In the model, morcellation indicated the cutting of uterine tissue to facilitate laparoscopic 
removal. Data are lacking regarding safety differences between various morcellation 
techniques, preventing stratification by type of morcellation. The few studies which 
demonstrate survival differences in leiomyosarcoma patients who underwent surgery with 
and without morcellation include a heterogeneous set of extraction modalities.7,8
Health state utilities capture health-related quality of life and are measured on a scale of 0 to 
1, where 0 represents death and 1 represents 1 year of life in perfect health. Each year of life 
spent at that health state can then be quantified in quality-adjusted life years. Using 
published literature, we derived utility estimates for each health state represented in the 
model as well as the average duration of each health state (Table 3).
To account for the possibility of experiencing multiple clinical events, each with varying 
duration and morbidity, we divided the 5-year (60-month) period into 1-month increments 
and used a selective weighted average to calculate 1-month utilities for each distinct 
pathway in the tree. We then summed across 5-years to obtain 5-year quality-adjusted life 
years for the laparoscopic and abdominal branches. To more accurately reflect real-world 
clinical scenarios, the model was built to reflect the fact that women could experience 
multiple clinical adverse events simultaneously (e.g., require a transfusion and have a wound 
infection). If events overlapped in time, the worse utility estimate was assigned for that 
period. We further assumed that death due to hysterectomy occurred immediately post-
operatively—i.e., at the beginning of our study window. Accordingly, these persons 
contributed a utility weight of 0 to the model. For leiomyosarcoma-related deaths, these 
persons experience the quality-adjusted life-years associated with first- and second-line 
chemotherapy, as well as subsequent palliative care, and are assumed to die in year 5 of the 
model, using 5-year survival estimates.
Deterministic (one-way univariate) sensitivity analyses were performed to assess the 
robustness of the assumptions in the decision model,27 including surgical complications, the 
probability of leiomyosarcoma, and probability of death from hysterectomy. The range of 
clinical outcomes (e.g. transfusion, wound infection, etc.) was evaluated by varying the input 
for each clinical event to its minimum and maximum. Given the limited reports on utilities 
for the health states in our model, we performed a sensitivity analysis by varying the utility 
by 20% higher and lower than each base-case estimate.
Results
The decision analysis predicted fewer overall deaths with laparoscopic hysterectomy 
compared to abdominal hysterectomy (98 vs. 103 per 100,000) (Table 4). While there were 
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more deaths from leiomyosarcoma following laparoscopic hysterectomy (86 vs. 71 per 
100,000), there were more hysterectomy-related deaths with abdominal hysterectomy (32 vs. 
12 per 100,000). For surgical complications, the laparoscopic group had lower rates of 
transfusion (2,400 vs. 4,700 per 100,000), wound infection (1,500 vs. 6,300 per 100,000), 
venous thromboembolism (690 vs. 840 per 100,000) and incisional hernia (710 vs. 8,800 per 
100,000), but a higher rate of vaginal cuff dehiscence (640 vs. 290 per 100,000), compared 
to the abdominal group.
In terms of quality of life, the laparoscopic group resulted in 499,171 quality-adjusted life 
years, compared to 490,711 in the abdominal group (incremental difference: 8,460 
additional quality-adjusted life years gained among women undergoing laparoscopic 
hysterectomy). Stated another way, on average, women undergoing laparoscopic 
hysterectomy experience an additional 0.85 quality-adjusted life years over 5 years (1.02 
months), compared to women undergoing abdominal hysterectomy.
In the sensitivity analysis, our results were relatively robust to varying risks of postoperative 
complications, leiomyosarcoma, and hysterectomy-associated deaths across predefined 
ranges in the published literature (Table 4). Using the lowest estimate of leiomyosarcoma 
(0.007), the incremental difference in the number of deaths per 100,000 ranged from 11 to 
19 more with abdominal hysterectomy, varying the rate of procedure-related death. With the 
high estimate (0.0049), the number ranged from 36 to 44 more deaths with laparoscopic 
hysterectomy. The incremental difference in death associated with laparoscopic 
hysterectomy was most conservative with the base-case estimates of procedure-related death 
(Figure 2). A hypothetical leiomyosarcoma incidence of 0.0015 would provide equivalent 
mortality between laparoscopic and abdominal groups, assuming base-case estimate for 
procedure-related death.
Quality-adjusted life year differences were robust across a +/− 20% utility range for 
sensitivity analysis. For example, if the hysterectomy utility estimate was, in fact, 0.72 rather 
than 0.9, the difference in total quality-adjusted life years over 5 years would be 16,438, 
with laparoscopic hysterectomy patients experiencing an additional 0.16 quality-adjusted life 
years over 5 years (1.97 months). Even without a decrement for hysterectomy, there 
remained a difference of 4,312 quality-adjusted life years (0.52 months). There was no 
scenario where a 20% adjustment in base-case utility resulted in more quality-adjusted life 
years for abdominal hysterectomy.
Comment
Using base-case estimates, our decision analysis predicted lower overall mortality from 
laparoscopic hysterectomy with morcellation than abdominal hysterectomy for treating the 
presumed fibroid uterus in premenopausal women. Abdominal hysterectomy was associated 
with more postoperative complications and lower quality of life.
A strength of the study includes its design as a decision analysis, a strategy particularly 
helpful when a comparative prospective study is challenging. In this case, it would not be 
feasible to conduct a randomized trial comparing laparoscopic hysterectomy with 
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morcellation to abdominal hysterectomy because leiomyosarcoma is so rare. Further, the 
analysis incorporated mortality due to the procedure itself, not simply mortality associated 
with morcellation of leiomyosarcoma. Insight was also provided for multiple clinical 
outcomes, offering more information to guide surgeons in counseling women on approach 
for hysterectomy for fibroids. Lastly, outcomes were assessed by comprehensive literature 
review, and sensitivity analyses supported the model's conclusions, adding confidence to the 
applicability of these findings to a clinical setting.
Any discussion of risk associated with morcellation of presumed leiomyomata is limited by 
the paucity of data regarding the incidence of occult leiomyosarcoma in this setting. 
Currently available reports include very small numerators and denominators when 
considering the high number of uterine surgeries for fibroids that occurred during the 
respective time periods.4, 17-25 The studies span several decades, with varying pathologic 
criteria to define leiomyosarcoma, and include data from five different countries. Some 
women in the reports were identified preoperatively and some included older, 
postmenopausal women. The population, therefore, does not necessarily reflect those at risk, 
as morcellation would not have been performed in the first place. Thus, limitations in the 
literature suggest our estimate was conservative, and updated estimates of leiomyosarcoma 
risk in this population are unlikely to alter the direction of our conclusions. Although the 
high end of leiomyosarcoma incidence in sensitivity analysis changed the direction of 
favorable mortality to abdominal hysterectomy, consideration of all the available literature 
suggests it is fair to at least grant near-equivalent mortality, with outcomes other than 
mortality still clearly favoring laparoscopy. Further, our estimates of mortality from the 
procedure itself were the most conservative of the candidates available in sensitivity 
analysis.
Data are limited regarding the specific impact of morcellation of occult leiomyosarcoma. 
The model assumed the behavior of a morcellated leiomyosarcoma would mimic that of 
spontaneous disease spread. A better understanding of the impact of leiomyosarcoma 
morcellation could alter the conclusions of our model, either positively or negatively.
The results are subject to uncertainty in the estimates of rare events such mortality. In 
particular, in the absence of randomization, unmeasured factors could influence the 
relationship between type of surgery and death. Further, randomized trials involving the 
specific target population were not always available, so we attempted to account for this 
uncertainty by conducting sensitivity analyses, varying point estimates of these events with 
ranges reported in existing literature.
Data were also limited in assigning utilities to various complications associated with 
hysterectomy, but our findings were robust to a 20% manipulation of the estimates. In all 
scenarios, laparoscopic hysterectomy was favored in terms of quality of life.
Finally, this analysis was conducted specifically on clinical outcomes. Assessing cost 
associated with surgery is notoriously difficult, but monetary estimates for the procedure and 
associated post-operative events could add depth to the consideration of approach for 
hysterectomy to treat leiomyomata. Not all clinical outcomes were assessed, but more recent 
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literature suggests the rate of visceral injury is not different between laparoscopic and 
abdominal hysterectomy.10 The outcomes included in our study are not as likely to change 
based on improvement in technique (e.g. venous thromboembolism), and, if anything, would 
favor a laparoscopic approach (e.g. blood loss).
Morcellation is currently one the most debated issues in gynecologic surgery, both in the 
media and in the medical arena, prompted by a recent Food and Drug Administration safety 
notification5 and the response of several large Obstetrics and Gynecology organizations 
regarding its use.28, 29 The Food and Drug Administration report emphasizes risk associated 
with morcellation, nearly to the exclusion of the benefits of minimally invasive surgery for 
leiomyomata.9, 15 The benefits could be further improved by reducing risk associated with 
morcellation (e.g. specimen containment) rather than abandoning minimally invasive 
treatment for fibroids. Better understanding of risk factors for leiomyosarcoma, new 
diagnostics to preoperatively distinguish benign from malignant myomata, and enhanced 
methods of tissue extraction represent potential avenues for improvement in the safety and 
care of women with uterine disease.
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Figure 1. Decision Tree
Premenopausal women requiring hysterectomy for an enlarged uterus could undergo 
laparoscopic or abdominal hysterectomy. In either approach, death could occur immediately 
after the procedure. Women who survive the procedure could experience immediate surgical 
complications (blood transfusion, wound infection, or vaginal cuff dehiscence) and/or longer 
term surgical complications (hernia and venous thromboembolism). Women who had occult 
leiomyosarcoma at the time of the procedure would undergo treatment, after which point 
they could recover or die (sarcoma-related death).
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Number of incremental deaths per 100,000 associated with laparoscopic hysterectomy by 
varying the candidates for leiomyosarcoma incidence used in the sensitivity analysis. At 
incidence of 0.007, 0.008, 0.009, and 0.0013, there were more deaths per 100,000 associated 
with abdominal hysterectomy. At incidence of 0.023, 0.027, and 0.049, there were more 
deaths per 100,000 associated with laparoscopic hysterectomy. (A) Base-case estimate: 
abdominal hysterectomy mortality 0.00032, laparoscopic hysterectomy mortality 0.00012. 
(B) Sensitivity analysis estimate #1: abdominal hysterectomy mortality 0.00038, 
laparoscopic hysterectomy mortality 0.00012. (C) Sensitivity analysis estimate #2: 
abdominal hysterectomy mortality 0.00038, laparoscopic hysterectomy mortality 0.000096. 
(D) Sensitivity analysis estimate #3 abdominal hysterectomy mortality 0.00032, 
laparoscopic hysterectomy mortality 0.000096.
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Table 2
Rate of leiomyosarcoma for women undergoing surgery for presumed fibroids
Study Publication Year Study Years Country Age (yrs) Leiomyosarcoma cases Total patients Rate of leiomyosarcoma
Leibsohn 17 1990 1983-1988 USA 36-62 7 1,429 0.0049
Reiter 18 1992 1986-1989 USA 42 (mean) 0 104 0.0
Parker 
*19 1994 1988-1992 USA 22-86 1 1,332 0.0008
Takamizawa 20 1999 1983-1997 Japan 26-75 1 923 0.0011
Sinha 
*21 2008 1998-2005 India 34 (mean) 2 505 0.0040
Kamikabeya 22 2010 1987-2008 Brazil Not reported 1 1,364 0.0007
Rowland 
†24 2011 2006-2011 USA Not reported 3 1,115 0.0027
Leung 23 2012 1999-2005 France 34-77 3 1,297 0.0023
Seidman 
*‡4 2012 1999-2010 USA Not reported 1 1,091 0.0009






Denominator included only morcellated cases
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Table 3
Utilities
Parameter Estimate Range 
* Duration (months) Source
Hysterectomy for fibroids
a 0.9 [0.72, 1.0] 6 O'Sullivan40
Transfusion 0.48 [0.38, 0.58] 1 Klarenbock41
Wound infection 0.607 [0.49, 0.73] 1 Chatterjee42
Vaginal cuff dehiscence 0.54 [0.43, 0.65] 1 Chatterjee42
Venous thromboembolism 0.8 [0.64, 0.96] 12 Spangler43
Hernia 0.77 [0.62, 0.92] 24 Hynes44
Leiomyosarcoma (1st 6 months chemotherapy) 
b 0.76 [0.61, 0.91] 6 Reichardt45
Leiomyosarcoma progression (additional 12-months 
chemotherapy) 
c
0.66 [0.53, 0.79] 12 Reichardt45
Leiomyosarcoma progression (palliative care) 
d 0.71 [0.57, 0.85] 36 Health Quality Ontario46
Alive 1.0 Not varied Varies
*
Range based on +/− 20% of base-case utility. If +20% exceeded 1.0, the utility was assigned a value of 1.0
a
Decrement applied only to abdominal hysterectomy
b
For women with leiomyosarcoma diagnosed at time of surgery, we presumed all would receive a minimum 6 months of chemotherapy 
(approximately 6 cycles). Responders would get no more treatment and return to normal health.
c
Non-responders after 6 months would get additional chemotherapy (up to 12 months).
d
Non-responders after 12 months of chemotherapy would go on to palliative care and ultimately die of their disease
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Table 4










Leiomyosarcoma cases 120 120 n/a
Leiomyosarcoma deaths 86 [50-353] 71 [41-289] 15
Hysterectomy-related deaths 12 [10-12] 32 [28-32] −20
Total deaths 98 [60-365] 103 [69-321] −5
Transfusion 2,400 [1,300-3,500] 4,700 [4,300-4,700] −2,300
Venous thromboembolism 690 [30-900] 840 [720-840] −150
Vaginal cuff dehiscence 640 [200-890] 290 [150-600] 350
Abdominal wound infection 1,500 [55-1,500] 6,300 [6,300] −4,800
Hernia 710 [140-900] 4,500 [4,500-9,800] −8,090
Quality-adjusted life years 499,171 [499,062-499,280] 490,711 [482,733-486,270] 8,460
*
Sensitivity analyses were conducted using the ranges outlined in Tables 1 and 3, i.e. the one-way sensitivity analysis for each input
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